论文部分内容阅读
一种经静脉使用的Pamidronate(商品名Aredia)已由美国食品与药物管理局批准作为与恶性肿瘤有关的中度或严重高血症的治疗。该药对骨质的溶解有抑制作用。研究表明,64％的患者采用该药治疗后24h血钙开始下降,约61％的患者接受60mg治疗,用药7天血钙恢复正常。接受90mg治疗的所有患者在7天内血钙恢复正常。不论是否有恶性肿瘤的骨转移,该药治疗均有效。在接受治疗的受试者中,27％出现一过性或轻微体温升高,接受90mg治疗的患者18％出现输液部位反应。该药使用剂量应根据基础血钙浓度决定,如果血钙为3.0～3.38mmol/L剂量60～90mg;如果血钙浓度3.38mmol/L用90mg。此种剂量从静脉内注入的时间应>24h。
One intravenous Pamidronate (trade name Aredia) has been approved by the U.S. Food and Drug Administration as a treatment for moderate or severe hyperlipidemia associated with malignancy. The drug has a suppressive effect on the dissolution of bone. Studies have shown that in 64% of patients treated with the drug 24 hours after the start of blood calcium decreased, about 61% of patients receiving 60mg treatment, 7 days of blood calcium returned to normal. All patients receiving 90 mg of treatment returned to normal within 7 days. The drug is effective regardless of whether there is bone metastases from a malignant tumor. In subjects treated, transient or mild hypothermia occurred in 27% of patients receiving treatment, and 18% of those receiving 90 mg had an infusion site reaction. The drug dose should be based on the basic blood calcium concentration, if the calcium is 3.0 ~ 3.38mmol / L dose 60 ~ 90mg; if the serum calcium concentration 3.38mmol / L with 90mg. This dose from intravenous injection time should be> 24h.